According to results shown in an editorial by Hans. H. Herfarth, MD, PhD from the University of North Carolina in Chapel Hill, Gerhard Rogler, MD, PhD from the University of Zurich in Switzerland and Peter D. R. Higgins, MD, PhD, MSc, from University of Michigan, 24% of physicians used the standard dosing regimen for induction of remission in hospitalized patients with severe UC. “There appears to be a sub rosa movement in the inflammatory bowel disease community to try accelerated infliximab in severe UC, and the Gibson study provides data to support this approach,” the researchers wrote .
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.